Molecular characterization of hepatitis C virus in liver disease patients in Botswana: a retrospective cross-sectional study.
Adult
Antiviral Agents
/ therapeutic use
Botswana
Carcinoma, Hepatocellular
/ virology
Cross-Sectional Studies
Drug Resistance, Viral
Female
Genotype
Hepacivirus
/ drug effects
Hepatitis C
/ drug therapy
Humans
Interferon-alpha
/ therapeutic use
Liver Neoplasms
/ virology
Male
Middle Aged
Mutation
Phylogeny
Pilot Projects
Retrospective Studies
Ribavirin
/ therapeutic use
Botswana
DAA
Genotypes
HCV
Hepatitis C virus
Mutations
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
22 Oct 2019
22 Oct 2019
Historique:
received:
10
07
2019
accepted:
26
09
2019
entrez:
24
10
2019
pubmed:
24
10
2019
medline:
25
12
2019
Statut:
epublish
Résumé
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease globally. Direct acting antivirals (DAAs) have proven effective in curing HCV. However, the current standard of care (SOC) in Botswana remains PEGylated interferon-α (IFN-α) with ribavirin. Several mutations have been reported to confer resistance to interferon-based treatments. Therefore, there is a need to determine HCV genotypes in Botswana, as these data will guide new treatment guidelines and understanding of HCV epidemiology in Botswana. This was a retrospective cross-sectional pilot study utilizing plasma obtained from 55 participants from Princess Marina Hospital in Gaborone, Botswana. The partial core region of HCV was amplified, and genotypes were determined using phylogenetic analysis. Four genotype 5a and two genotype 4v sequences were identified. Two significant mutations - K10Q and R70Q - were observed in genotype 5a sequences and have been associated with increased risk of hepatocellular carcinoma (HCC), while R70Q confers resistance to interferon-based treatments. Genotypes 5a and 4v are circulating in Botswana. The presence of mutations in genotype 5 suggests that some patients may not respond to IFN-based regimens. The information obtained in this study, in addition to the World health organization (WHO) recommendations, can be utilized by policy makers to implement DAAs as the new SOC for HCV treatment in Botswana.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease globally. Direct acting antivirals (DAAs) have proven effective in curing HCV. However, the current standard of care (SOC) in Botswana remains PEGylated interferon-α (IFN-α) with ribavirin. Several mutations have been reported to confer resistance to interferon-based treatments. Therefore, there is a need to determine HCV genotypes in Botswana, as these data will guide new treatment guidelines and understanding of HCV epidemiology in Botswana.
METHODS
METHODS
This was a retrospective cross-sectional pilot study utilizing plasma obtained from 55 participants from Princess Marina Hospital in Gaborone, Botswana. The partial core region of HCV was amplified, and genotypes were determined using phylogenetic analysis.
RESULTS
RESULTS
Four genotype 5a and two genotype 4v sequences were identified. Two significant mutations - K10Q and R70Q - were observed in genotype 5a sequences and have been associated with increased risk of hepatocellular carcinoma (HCC), while R70Q confers resistance to interferon-based treatments.
CONCLUSION
CONCLUSIONS
Genotypes 5a and 4v are circulating in Botswana. The presence of mutations in genotype 5 suggests that some patients may not respond to IFN-based regimens. The information obtained in this study, in addition to the World health organization (WHO) recommendations, can be utilized by policy makers to implement DAAs as the new SOC for HCV treatment in Botswana.
Identifiants
pubmed: 31640596
doi: 10.1186/s12879-019-4514-1
pii: 10.1186/s12879-019-4514-1
pmc: PMC6805647
doi:
Substances chimiques
Antiviral Agents
0
Interferon-alpha
0
Ribavirin
49717AWG6K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
875Subventions
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Organisme : Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative
ID : DEL-15-006
Références
J Virol. 2009 Jul;83(13):6922-8
pubmed: 19369330
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
Hepatology. 2015 Aug;62(2):334-6
pubmed: 25892650
Clin Infect Dis. 2006 Dec 15;43(12):1612-5
pubmed: 17109297
Hepatology. 2010 Aug;52(2):421-9
pubmed: 20648473
J Med Virol. 2012 Apr;84(4):601-7
pubmed: 22337299
PLoS One. 2017 Jun 1;12(6):e0179064
pubmed: 28570623
Infect Genet Evol. 2014 Jan;21:118-23
pubmed: 24220189
BMC Genomics. 2016 Mar 17;17:247
pubmed: 26988550
J Clin Microbiol. 2015 Jan;53(1):219-26
pubmed: 25378574
Hepatology. 2008 Dec;48(6):1769-78
pubmed: 19026009
Virology. 2014 Sep;464-465:233-243
pubmed: 25105489
J Viral Hepat. 2014 May;21 Suppl 1:34-59
pubmed: 24713005
Clin Cancer Res. 2009 May 1;15(9):3205-13
pubmed: 19383824
BMC Infect Dis. 2016 Aug 09;16:391
pubmed: 27507267
Mol Biol Evol. 2012 Aug;29(8):1969-73
pubmed: 22367748
J Hepatol. 2010 Jan;52(1):72-8
pubmed: 19910070
Int J Mol Med. 2013 Feb;31(2):347-52
pubmed: 23241873
Am J Trop Med Hyg. 2011 Aug;85(2):390-4
pubmed: 21813864
J Hepatol. 2015 Dec;63(6):1323-33
pubmed: 26220749
Antiviral Res. 2016 Mar;127:90-8
pubmed: 26704023
J Gen Virol. 1994 Jul;75 ( Pt 7):1761-8
pubmed: 8021605
Virus Genes. 2019 Feb;55(1):33-42
pubmed: 30382563
Virology. 1999 Sep 1;261(2):263-70
pubmed: 10497111
World J Gastroenterol. 2016 Sep 14;22(34):7824-40
pubmed: 27678366
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Hepatology. 2006 Nov;44(5):1355-61
pubmed: 17058236
J Clin Microbiol. 2003 Nov;41(11):5240-4
pubmed: 14605173
Cancer Sci. 2009 Dec;100(12):2465-8
pubmed: 20175782